Pharmaceuticals News and Research

RSS

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.

18 Nov 2014

Three-day global symposium on Ebola virus, other infectious diseases

The 11th annual International Consortium on Anti-Virals (ICAV) symposium, Infectious Diseases: Global Public-Health Challenges of the Next Decade, will put the challenges posed by several infectious diseases under the microscope, including the Ebola virus, the H7N9 influenza virus, MERS coronavirus and dengue viruses, as well as drug-resistant tuberculosis.

18 Nov 2014

IntelliCap electronic oral drug delivery technology wins prestigious European ‘High-Tech Innovation Award’

The IntelliCap electronic oral drug delivery technology, created by medtech innovator Medimetrics, has won a prestigious European ‘High-Tech Innovation Award’ from Accenture, the global management consultancy.

18 Nov 2014

Pros and cons of medical marijuana to be discussed at Queensland Epilepsy Symposium

The pros and cons of medical marijuana is a discussion focus at the fifth annual Queensland Epilepsy Symposium, Epilepsy – On the Horizon.

18 Nov 2014

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today presented detailed results from HARMONIZE (ZS004) at the late-breaking Clinical Science Special Reports Session of the American Heart Association Scientific Sessions.

18 Nov 2014

New preclinical study shows RG-012 may provide therapeutic benefit for Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA.

18 Nov 2014

EKF Diagnostics and Joslin Diabetes Center enter collaborative relationship

EKF, has entered a collaborative relationship with Joslin Diabetes Center in support of the ongoing clinical and commercial translation of TNFR1 & 2 biomarkers.

From EKF Diagnostics 17 Nov 2014

Chemical compound in coffee may help prevent damaging effects of obesity

Researchers at the University of Georgia have discovered that a chemical compound commonly found in coffee may help prevent some of the damaging effects of obesity.

17 Nov 2014

New test can detect bloodstream infection with unprecedented speed, sensitivity

A new bloodstream infection test created by UC Irvine researchers can speed up diagnosis times with unprecedented accuracy, allowing physicians to treat patients with potentially deadly ailments more promptly and effectively.

16 Nov 2014

Anthera Pharmaceuticals reports net loss of $7.0 million for third quarter 2014

Anthera Pharmaceuticals, Inc., today announced financial results and operational update for the third quarter ended September 30, 2014.

16 Nov 2014

Grey Group Singapore honored at New York Festivals' Global Awards

This year's New York Festivals' Global Awards saw Grey Group Singapore sweep the healthcare awards including clinching the prestigious Grand Global award, five Global awards and three finalist certificates.

16 Nov 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, today reported financial results for the three and nine months ended September 30, 2014.

14 Nov 2014

Valeant Pharmaceuticals hosts ribbon-cutting ceremony to celebrate renovation of U.S. headquarters in NJ

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today celebrated the completion of renovations to its U.S. headquarters in Bridgewater, New Jersey with a ribbon-cutting ceremony.

14 Nov 2014

China Pharma’s revenues decrease $5.5M to 31% in third quarter 2014

China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma" or the "Company"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its financial results for the three months ended September 30, 2014.

14 Nov 2014

New anti-cancer drug may protect normal cells against radiation

Although radiation treatments have become much more refined in recent years, it remains a challenge to both sufficiently dose the tumor while sparing the surrounding tissue.

14 Nov 2014

Focusing on comorbidity and disabilities can reduce healthcare costs in aging population

As our society ages, a University of Montreal study suggests the health system should be focusing on comorbidity and specific types of disabilities that are associated with higher health care costs for seniors, especially cognitive disabilities.

14 Nov 2014

Laurus Labs to use Novasep Varicol continuous chromatography system

Novasep, a leading supplier of manufacturing solutions to the life sciences industry, and its long-time partner Nilsan Nishotech Systems, a specialist in process engineering in India, today announce the commissioning of a continuous chromatography Varicol system at Laurus Labs, one of India’s fastest growing API (Active Pharmaceutical Ingredients) makers.

14 Nov 2014

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.

14 Nov 2014

Cornerstone's CPI-613 drug candidate chosen as 2014 Top 10 Most Interesting Oncology Projects to Watch

Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced that its lead compound CPI-613 has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch.

14 Nov 2014